F8 IL10

Drug Profile

F8 IL10

Alternative Names: Dekavil; F8-IL10; PF 06687234

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Philogen
  • Developer Pfizer; Philogen
  • Class Antirheumatics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Inflammation

Most Recent Events

  • 06 Oct 2016 Pfizer terminates a phase I trial in Inflammation (In volunteers) in USA due to the potential risk of further dosing in healthy subjects (NCT02711462)
  • 01 Feb 2016 Phase-I clinical trials in Inflammation (In volunteers) in USA (IV and SC) (NCT02711462)
  • 01 Oct 2014 Phase-II clinical trials in Rheumatoid arthritis in Italy (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top